DiscGenics CEO Flagg Flanagan Highlighted Launch of FDA-Approved Phase 3 Program for IDCT (rebonuputemcel) at CG 2026 Musculoskeletal Conference

Salt Lake City, UT — March 4, 2026 — DiscGenics, Inc., a privately held, late-stage clinical biopharmaceutical company focused on developing regenerative cell-based therapies that alleviate pain and restore function in patients with degenerative diseases of the spine, today announced that Flagg Flanagan, Chief Executive Officer and Chairman of DiscGenics presented at the CG 2026 Musculoskeletal Conference.

CG 2026 Musculoskeletal Conference held in New Orleans, Louisiana.
    Title:          Revolutionizing Care for Chronic Back Pain
    Date:          Monday, March 2, 2026
    Time:          4:00 PM
    Location:    New Orleans, Louisiana

During the presentation, Flanagan highlighted DiscGenics’ advancement of IDCT (rebonuputemcel), including the launch of the Company’s FDA-approved Phase 3 clinical program for symptomatic, lumbar degenerative disc disease, and outlined the study design and key milestones supporting DiscGenics’ path toward commercialization.

A public video recording of DiscGenics’ company presentation can be viewed here:

About DiscGenics

DiscGenics is a privately held, late-stage clinical, biopharmaceutical company developing cell-based regenerative therapies that alleviate pain and restore function in patients with degenerative diseases of the spine. DiscGenics’s first product candidate, IDCT (rebonuputemcel), is an allogeneic, injectable discogenic progenitor cell therapy for symptomatic, lumbar disc degeneration. IDCT is a mixture of live Discogenic Cells, which are a manufactured progenitor cell population derived from donated adult human intervertebral disc tissue, and a viscous carrier. IDCT has been granted regenerative medicine advanced therapy (RMAT) and Fast Track designations by the U.S. Food and Drug Administration. As the only company in the world to develop an allogeneic cell therapy derived from intervertebral disc cells to treat diseases of the disc, DiscGenics has a unique opportunity to offer a non-surgical, potentially regenerative solution for the treatment of patients suffering from the debilitating effects of back pain.

DiscGenics has developed a proprietary, commercial-scale, in-house allogeneic cell manufacturing process and built and qualified a cGMP facility at its Salt Lake City, Utah headquarters.

For more information, visit discgenics.com